Factor IX polypeptides and methods of use thereof
AssigneeBioverativ Therapeutics Inc.
InventorsGlenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
Claims25
A method of controlling a bleeding episode in a human subject having hemophilia B, comprising intravenously administering to the subject multiple doses of about 25 IU/kg to about 50 IU/kg of a chimeric polypeptide comprising Factor IX (FIX) and a FcRn binding partner (FcRn BP) at a dosing interval of about 7 days between two doses, wherein the FcRn BP comprises Fc or albumin and wherein the subject exhibits a trough level of the plasma FIX activity of at least 3 IU/dL after six days each administration.
A method of prophylactic treatment of hemophilia B in a human subject in need thereof, comprising administering to the subject multiple doses of about 25 IU/kg to about 50 IU/kg of a chimeric polypeptide comprising Factor IX (FIX) and a FcRn binding partner (FcRn BP) at a dosing interval of about 7 days between two doses, wherein the FcRn BP comprises Fc or albumin and wherein the subject exhibits a trough level of the plasma FIX activity of at least 3 IU/dL after six days each administration.
Dependencies are inferred from the claim text.